tetano
Editor, Senior Moderator
Vaccine
. 2024 Aug 15;42(22):126223.
doi: 10.1016/j.vaccine.2024.126223. Online ahead of print. Efficacy and safety of Abdala COVID-19 subunit vaccine in children and adolescents: An open-label, single-arm, phase 2 trial (MEÑIQUE)
Francisco Hernández-Bernal[SUP] 1 [/SUP], Enrique Noa-Romero[SUP] 2 [/SUP], Joel Quintana-Guerra[SUP] 3 [/SUP], Cristina O Chávez-Chong[SUP] 4 [/SUP], Yenima Martín-Bauta[SUP] 3 [/SUP], Laura Alvaré-Alvaré[SUP] 5 [/SUP], Alena Salvato-Dueñas[SUP] 5 [/SUP], Danusia Felipe-Mallea[SUP] 5 [/SUP], Mairalys Porta-Díaz[SUP] 5 [/SUP], Otto Cruz-Sui[SUP] 2 [/SUP], Karen Urrutia-Pérez[SUP] 3 [/SUP], Klaudia Urrutia-Pérez[SUP] 3 [/SUP], José L Rodríguez-Reinoso[SUP] 3 [/SUP], Marel Alonso-Valdés[SUP] 3 [/SUP], Zurina Cinza-Estévez[SUP] 3 [/SUP], Aylin Rodríguez-Triana[SUP] 5 [/SUP], Yolanda Cruz-Gómez[SUP] 5 [/SUP], Miladys Limonta-Fernández[SUP] 3 [/SUP], Mireida Rodríguez-Acosta[SUP] 2 [/SUP], Marta Ayala-Ávila[SUP] 3 [/SUP], Verena L Muzio-González[SUP] 3 [/SUP]; ABDALA Group of Investigators
Affiliations
Objectives We evaluated the safety, immunogenicity and efficacy of Abdala, a protein subunit vaccine for 2019 coronavirus disease (COVID-19), in children and adolescents. Methods A phase 2, open-label, single-arm clinical trial was carried out. Subjects aged 3 to 18 years were eligible. Abdala vaccine was administered intramuscularly at 0-14-28 days. The main endpoints were safety and the immunobridging analysis with a non-inferiority design, to infer the efficacy of the vaccine in paediatric population based on the comparison of neutralizing antibodies (NAb) to SARS-CoV-2, with adults (19-21 years). The trial is registered with the Cuban Public Registry of Clinical Trials, RPCEC00000390. Results From September 13th to September 17th, 2021, 703 participants were included in the context of a predominantly SARS-CoV-2 Delta variant circulation. The number of individuals who experienced adverse reactions was 264/703 (37·6%). Adverse reactions were mostly mild and occurred at the injection site, which resolved within the first 24-48 h. There were no reports of severe adverse events. For the non-inferiority comparison of 297 children (3-11 years) with 297 adults, the geometric mean (GMT) ratio of SARS-CoV-2 NAb was 0·87 (95% CI 0·69-1·08) and 1·07 (0·82-1·39) in the same comparison for 203 adolescents (12-18 years) and 203 adults. For both age groups, the lower limit of GMT was higher than 0·67. The differences in seroresponse rates of Nab for children were 1% (-2%, 4%) and -3% (-7%, 1%) for adolescents, higher than -10% in both age groups. Conclusions The Abdala vaccine was safe and immunogenic in a paediatric population aged 3-18 years, with inferred efficacy based on non-inferior analysis. The vaccine is very suitable to fit into massive vaccination strategies, considering the advantages of using the same vaccine strength (RBD 50 μg) and schedule of administration for both adults and children, as well as the easy storage and handling conditions at 2-8 °C.
Keywords: COVID-19; Children; Clinical trial; Immunobridging; Neutralizing antibodies; SARS-CoV-2; Vaccine.
. 2024 Aug 15;42(22):126223.
doi: 10.1016/j.vaccine.2024.126223. Online ahead of print. Efficacy and safety of Abdala COVID-19 subunit vaccine in children and adolescents: An open-label, single-arm, phase 2 trial (MEÑIQUE)
Francisco Hernández-Bernal[SUP] 1 [/SUP], Enrique Noa-Romero[SUP] 2 [/SUP], Joel Quintana-Guerra[SUP] 3 [/SUP], Cristina O Chávez-Chong[SUP] 4 [/SUP], Yenima Martín-Bauta[SUP] 3 [/SUP], Laura Alvaré-Alvaré[SUP] 5 [/SUP], Alena Salvato-Dueñas[SUP] 5 [/SUP], Danusia Felipe-Mallea[SUP] 5 [/SUP], Mairalys Porta-Díaz[SUP] 5 [/SUP], Otto Cruz-Sui[SUP] 2 [/SUP], Karen Urrutia-Pérez[SUP] 3 [/SUP], Klaudia Urrutia-Pérez[SUP] 3 [/SUP], José L Rodríguez-Reinoso[SUP] 3 [/SUP], Marel Alonso-Valdés[SUP] 3 [/SUP], Zurina Cinza-Estévez[SUP] 3 [/SUP], Aylin Rodríguez-Triana[SUP] 5 [/SUP], Yolanda Cruz-Gómez[SUP] 5 [/SUP], Miladys Limonta-Fernández[SUP] 3 [/SUP], Mireida Rodríguez-Acosta[SUP] 2 [/SUP], Marta Ayala-Ávila[SUP] 3 [/SUP], Verena L Muzio-González[SUP] 3 [/SUP]; ABDALA Group of Investigators
Affiliations
- PMID: 39151232
- DOI: 10.1016/j.vaccine.2024.126223
Objectives We evaluated the safety, immunogenicity and efficacy of Abdala, a protein subunit vaccine for 2019 coronavirus disease (COVID-19), in children and adolescents. Methods A phase 2, open-label, single-arm clinical trial was carried out. Subjects aged 3 to 18 years were eligible. Abdala vaccine was administered intramuscularly at 0-14-28 days. The main endpoints were safety and the immunobridging analysis with a non-inferiority design, to infer the efficacy of the vaccine in paediatric population based on the comparison of neutralizing antibodies (NAb) to SARS-CoV-2, with adults (19-21 years). The trial is registered with the Cuban Public Registry of Clinical Trials, RPCEC00000390. Results From September 13th to September 17th, 2021, 703 participants were included in the context of a predominantly SARS-CoV-2 Delta variant circulation. The number of individuals who experienced adverse reactions was 264/703 (37·6%). Adverse reactions were mostly mild and occurred at the injection site, which resolved within the first 24-48 h. There were no reports of severe adverse events. For the non-inferiority comparison of 297 children (3-11 years) with 297 adults, the geometric mean (GMT) ratio of SARS-CoV-2 NAb was 0·87 (95% CI 0·69-1·08) and 1·07 (0·82-1·39) in the same comparison for 203 adolescents (12-18 years) and 203 adults. For both age groups, the lower limit of GMT was higher than 0·67. The differences in seroresponse rates of Nab for children were 1% (-2%, 4%) and -3% (-7%, 1%) for adolescents, higher than -10% in both age groups. Conclusions The Abdala vaccine was safe and immunogenic in a paediatric population aged 3-18 years, with inferred efficacy based on non-inferior analysis. The vaccine is very suitable to fit into massive vaccination strategies, considering the advantages of using the same vaccine strength (RBD 50 μg) and schedule of administration for both adults and children, as well as the easy storage and handling conditions at 2-8 °C.
Keywords: COVID-19; Children; Clinical trial; Immunobridging; Neutralizing antibodies; SARS-CoV-2; Vaccine.